SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Kahan T) srt2:(2005-2009)"

Sökning: WFRF:(Kahan T) > (2005-2009)

  • Resultat 11-20 av 49
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  •  
12.
  • Kahan, T (författare)
  • Delapril/manidipine
  • 2006
  • Ingår i: DRUGS. - : Springer Science and Business Media LLC. - 0012-6667. ; 66:7, s. 970-970
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
13.
  •  
14.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  •  
19.
  • Laska, AC, et al. (författare)
  • Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study
  • 2005
  • Ingår i: Cerebrovascular diseases (Basel, Switzerland). - : S. Karger AG. - 1015-9770 .- 1421-9786. ; 19:2, s. 125-132
  • Tidskriftsartikel (refereegranskat)abstract
    • <i>Background and Purpose:</i> Pharmacotherapy aimed at stroke rehabilitation through direct central nervous effects may be assumed to work in a similar way for language recovery and sensory-motor recovery. Some data suggest that antidepressant drugs could be beneficial also for functional improvement. This prompted us to investigate whether regression from aphasia after acute stroke could be enhanced by antidepressive drug therapy. <i>Methods:</i> We randomised 90 acute stroke patients with aphasia to either 600 mg moclobemide or placebo daily for 6 months, within 3 weeks of the onset of stroke. Aphasia was assessed prior to treatment and at 6 months, using Reinvang’s ‘Grunntest for afasi’ and the Amsterdam-Nijmegen-Everyday-Language-Test (ANELT). <i>Result:</i> The degree of aphasia decreased significantly at 6 months, with no difference between the moclobemide- and the placebo-treated groups. Multivariate regression analysis including treatment group, activities of daily living, aetiology of stroke, ANELT, and Reinvang’s coefficient at baseline, and neurological deficit confirmed these results. In all, 13 in the moclobemide and 10 in the placebo group stopped taking the study medication. No further change was found in the 56 aphasic patients followed up for another 6 months with no medication. <i>Conclusions:</i> Compared to placebo, treatment with moclobemide for 6 months did not enhance the regression of aphasia following an acute stroke.
  •  
20.
  • Laska, AC, et al. (författare)
  • Recognition of depression in aphasic stroke patients
  • 2007
  • Ingår i: Cerebrovascular diseases (Basel, Switzerland). - : S. Karger AG. - 1015-9770 .- 1421-9786. ; 24:1, s. 74-79
  • Tidskriftsartikel (refereegranskat)abstract
    • <i>Background:</i> Data on post-stroke depression in aphasia are scarce. <i>Methods:</i> Eighty-nine acute stroke patients with aphasia of all types were followed for 6 months to investigate if depression can be reliably diagnosed (DSM-IV criteria) and validly assessed by the verbal Montgomery-Åsberg Depression Rating Scale (MADRS) and a global technique (Clinical Global Impressions Rating Scale for Severity). A standard aphasia test was performed. <i>Results:</i> In 60 patients (67%) at baseline and in 100% at 6 months, comprehension allowed a reliable DSM-IV diagnosis. Among these patients MADRS was feasible in 95% at baseline and in 100% at 6 months. The assistance of relatives and staff increases the feasibility and decreases the validity. Depression was identified in 24% during the 6 months. <i>Conclusion:</i> Depression diagnosis and severity rating can reliably be made in the acute phase in at least two thirds of aphasic patients, and feasibility increases over time.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 49

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy